Taxane

Phase 3Small molecule

Bristol-Myers Squibb

Taxane is one of 128 small molecule programs targeting Esophageal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal AdenocarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

Breast CancerWithdrawn

Advanced or Metastatic Solid TumorsRecruiting

Esophageal AdenocarcinomaPreclinical

Active, not recruiting

Cervical CancerPreclinical

Active, not recruiting

Breast CancerPhase 3

Withdrawn

Advanced or Metastatic Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Taxane

Bristol-Myers Squibb

Phase 3

7 2

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 3

Tricor

JJagotec

Preclinical

1 4

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 7

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT07158918

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT06102824

Q4 2029

Phase 3Active, not recruiting

Breast Cancer; HER2-Positive; Metastatic

NCT04784715

Q4 2032

Phase 2Not yet recruiting

Breast Cancer

NCT07716046

Clinical

Trials by Indication[1]

Breast Cancer7 trials

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

Active, not recruiting·YYonsei University·Phase 3·NCT02441933·878 enrolled

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06102824·252 enrolled

A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00475670·44 enrolled

Show 4 more trials

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting·SSpanish Breast Cancer Research Group·Phase 2·NCT04293393·200 enrolled

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Withdrawn·PPeregrine Pharmaceuticals·Phase 2/3·NCT02651610

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Withdrawn·PPeregrine Pharmaceuticals·Phase 2·NCT02685306

Efficacy and Safety of Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for First-line Maintenance or Upfront Chemo-Free Treatment in HR+/HER2+ Advanced Breast Cancer: A Multicenter, Open-label, Randomized Controlled Phase II Study

Not yet recruiting·FFudan University·Phase 2·NCT07716046·240 enrolled

Ovarian Cancer2 trials

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Terminated·MMorphotek·Phase 3·NCT00849667·1,100 enrolled

Advanced Cancer2 trials

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00326131·6 enrolled

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00332748·36 enrolled

Advanced or Metastatic Solid Tumors1 trial

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Recruiting·AABL Bio, Inc.·Phase 1/2·NCT07158918·65 enrolled

Cervical Cancer1 trial

Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)

Unknown status·SSun Yat-sen University·N/A·NCT02624531·60 enrolled

7 more indications

Esophageal Adenocarcinoma1 trial

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Completed·—··NCT04920747·65 enrolled

Randomized1 trial

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

Completed·NNew Mexico Cancer Research Alliance·Phase 3·NCT00277043·200 enrolled

Biomarkers1 trial

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated·UUniversity of Wisconsin, Madison··NCT03393741·5 enrolled

Gastric Cancer1 trial

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Terminated· Roche logo

Roche·Phase 2/3·NCT01641939·415 enrolled

Lymphoma1 trial

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Completed· Bayer logo

Bayer·Phase 2·NCT00044551·29 enrolled

Non-Small Cell Lung Cancer1 trial

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00103831

Breast Cancer; HER2-positive; Metastatic1 trial

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04784715·1,157 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Taxane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taxane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taxane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Taxane

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2029

Q4 2032

Trials by Indication[1]

Breast Cancer7 trials

Ovarian Cancer2 trials

Advanced Cancer2 trials

Advanced or Metastatic Solid Tumors1 trial

Cervical Cancer1 trial

Esophageal Adenocarcinoma1 trial

Randomized1 trial

Biomarkers1 trial

Gastric Cancer1 trial

Lymphoma1 trial

Non-Small Cell Lung Cancer1 trial

Breast Cancer; HER2-positive; Metastatic1 trial

References

Drug Info

Quick Facts

Related News